199 related articles for article (PubMed ID: 27760600)
1. [Treatment of Advanced Squamous Cell Lung Cancer].
Zhu Y; Xing P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):687-691. PubMed ID: 27760600
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients.
Zhang Q; Zhu L; Zhang J
BMC Cancer; 2015 Mar; 15():88. PubMed ID: 25886585
[TBL] [Abstract][Full Text] [Related]
3. [Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].
Xiong B; Ke W; Jiang W
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):283-290. PubMed ID: 38769831
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.
Yoshimatsu Y; Ebi N; Ooi R; Sueyasu T; Nishizawa S; Munechika M; Yoshimine K; Ko Y; Ide H; Tsuruno K; Tobino K
Intern Med; 2021 Apr; 60(7):1067-1071. PubMed ID: 33132329
[TBL] [Abstract][Full Text] [Related]
7. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Takeda M; Okamoto I; Nakagawa K
J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
Xu Z; Hao X; Lin L; Li J; Xing P
Thorac Cancer; 2021 Aug; 12(16):2233-2240. PubMed ID: 34180588
[TBL] [Abstract][Full Text] [Related]
11. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with
Rekowska A; Rola P; Wójcik-Superczyńska M; Chmielewska I; Krawczyk P; Milanowski J
Curr Oncol; 2022 May; 29(5):3531-3539. PubMed ID: 35621675
[TBL] [Abstract][Full Text] [Related]
14. T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Kusaba Y; Takeda Y; Abe S; Tsukada A; Naka G
Medicine (Baltimore); 2022 Aug; 101(32):e29682. PubMed ID: 35960133
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutation p.A864V in small cell lung cancer and lung squamous cell carcinoma: a case report and review of literature.
Deng W; Chen G; Xiong D; He R; Wang K; Lu H; Kong J
Anticancer Drugs; 2022 Oct; 33(9):979-982. PubMed ID: 35946520
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
[TBL] [Abstract][Full Text] [Related]
17. [Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].
Wang ZH; Song XY
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):90-93. PubMed ID: 28219201
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A
Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
[TBL] [Abstract][Full Text] [Related]
19. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
